Biodexa Pharmaceticals
Price & Volume
Stats
See more52W Range | $3.58-$74 |
Market Cap | $2.6M |
Shares Short | 38,911 |
Financials
See moreRevenue (12 Mos) | $83,000 |
Revenue Growth (YoY) | -64.1% |
Gross Profit (12 Mos) | -$4.9M |
Diluted EPS | -$26.50 |
News
See moreYahoo Finance • 27 days ago
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
Yahoo Finance • 2 months ago
Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025
Yahoo Finance • 2 months ago
Biodexa Pharmaceuticals files $100M shelf for flexible securities offerings
Yahoo Finance • 3 months ago
Biodexa Pharmaceuticals GAAP EPS of £0.00
About
CEO | Mr. Stephen Anthony Stamp |
CFO | Mr. Stephen Anthony Stamp |
Address | 1 Caspian Point, Cardiff, United Kingdom, CF10 4DQ |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 13 |
